Qiagen (NYSE:QGEN) Issues Q3 2026 Earnings Guidance

Qiagen (NYSE:QGEN) updated its third quarter 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 0.620- for the period, compared to the consensus EPS estimate of 0.630. The company issued revenue guidance of $538.3 million-$543.7 million, compared to the consensus revenue estimate of $552.7 million.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. TD Cowen reaffirmed a “hold” rating on shares of Qiagen in a report on Wednesday, July 15th. Kepler Capital Markets set a $38.60 price objective on shares of Qiagen and gave the company a “hold” rating in a research note on Thursday, June 25th. Berenberg Bank set a $45.50 price objective on shares of Qiagen and gave the company a “hold” rating in a research note on Tuesday, July 14th. Robert W. Baird set a $43.00 price objective on shares of Qiagen and gave the company an “outperform” rating in a research report on Wednesday, April 29th. Finally, Stifel Nicolaus set a $36.00 target price on Qiagen and gave the stock a “hold” rating in a research note on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Qiagen currently has an average rating of “Hold” and an average price target of $42.43.

Qiagen Price Performance

NYSE:QGEN traded down $0.24 during trading hours on Thursday, hitting $41.71. The company’s stock had a trading volume of 4,028,165 shares, compared to its average volume of 2,442,216. Qiagen has a twelve month low of $32.53 and a twelve month high of $57.81. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.21 and a quick ratio of 2.57. The stock has a fifty day simple moving average of $39.21 and a 200-day simple moving average of $41.73. The company has a market capitalization of $8.59 billion, a P/E ratio of 21.78, a PEG ratio of 4.22 and a beta of 0.63.

Qiagen (NYSE:QGEN) last issued its earnings results on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.60 by $0.02. The firm had revenue of $535.00 million during the quarter, compared to the consensus estimate of $527.50 million. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.The business’s quarterly revenue was up .2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.60 earnings per share. Qiagen has set its FY 2026 guidance at 2.430- EPS. On average, analysts anticipate that Qiagen will post 2.43 EPS for the current fiscal year.

Qiagen Increases Dividend

The business also recently declared an annual dividend, which was paid on Tuesday, July 14th. Investors of record on Tuesday, July 7th were issued a dividend of $0.35 per share. This is a boost from Qiagen’s previous annual dividend of $0.26. The ex-dividend date of this dividend was Tuesday, July 7th. This represents a dividend yield of 90.0%. Qiagen’s payout ratio is presently 18.32%.

Key Headlines Impacting Qiagen

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Qiagen exceeded its second-quarter outlook, reporting $535 million in sales and adjusted diluted EPS of $0.62, compared with analyst estimates of $527.5 million and $0.60, respectively. Sales were roughly flat year over year but better than the company’s prior expectation for an approximately 2% constant-exchange-rate decline. QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
• Positive Sentiment: The company reaffirmed its full-year 2026 adjusted EPS outlook of approximately $2.43, in line with consensus, while maintaining solid profitability. Its growth pillars reportedly delivered 5% constant-exchange-rate growth, supporting the case for continued demand in key molecular diagnostics and life-sciences markets. Qiagen N.V. 2026 Q2 Results Earnings Call Presentation
• Neutral Sentiment: Qiagen’s second-quarter net margin was 19.16%, and revenue increased approximately 0.2% year over year. However, the earnings beat was modest, with EPS declining from $0.63 a year earlier to $0.62, indicating limited earnings growth so far.
• Negative Sentiment: Qiagen guided third-quarter 2026 EPS to approximately $0.62, below the $0.63 consensus estimate, and revenue to $538.3 million-$543.7 million, below analysts’ $552.7 million forecast. The revenue shortfall is likely the key reason for the stock’s weaker performance, despite the second-quarter beat. Full-year revenue guidance of roughly $2.1 billion also remains below the approximately $2.2 billion consensus expectation.

Institutional Trading of Qiagen

A number of hedge funds have recently added to or reduced their stakes in QGEN. United Services Automobile Association acquired a new position in shares of Qiagen during the first quarter worth $239,000. Prudential Financial Inc. boosted its holdings in shares of Qiagen by 74.9% during the 2nd quarter. Prudential Financial Inc. now owns 8,873 shares of the company’s stock valued at $426,000 after acquiring an additional 3,799 shares in the last quarter. Invesco Ltd. grew its position in Qiagen by 123.7% during the 2nd quarter. Invesco Ltd. now owns 1,006,025 shares of the company’s stock worth $48,350,000 after acquiring an additional 556,387 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Qiagen by 226.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,598 shares of the company’s stock worth $125,000 after acquiring an additional 1,802 shares during the last quarter. Finally, First Trust Advisors LP bought a new stake in Qiagen during the 2nd quarter worth $3,639,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.